Eli Lilly's valuation is a critical concern, but its robust execution has improved its ability to actualize its high-growth ...

A handful boys soccer title contenders are sorting things out and putting the past behind them after some head-scratcher results during the past three weeks.

Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

Results from a late-stage study on RHHBY's Xofluza show that the drug reduces the transmission of influenza from an infected ...

Eli Lilly & Co. is asking people who took copies of its blockbuster weight loss drug to give the company access to their ...

Shares of Eli Lilly & Co. LLY advanced 1.11% to $915.04 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 1.70% to 5,713.64 and ...

As part of the acquisition, Organon will acquire psoriasis treatment Vtama, which could soon be approved in atopic dermatitis ...

Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery ...

This is thanks to Lilly's dominance in the billion-dollar weight loss drug market. Lilly's Mounjaro and Zepbound have helped ...

Researchers reported at the ESMO Congress that 78 percent of patients responded to front-line treatment with Lumakras, ...

The FDA’s approval of Kisunla demonstrates a positive change in Alzheimer disease management. Offering illness pathology therapy and the option of treatment conclusion after reaching therapeutic goals ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any breaking news developments ...